Managers / Q2 2022 · view latest →
Alerce Investment Management, L.P.
CIK 0001844002 · 676 N. MICHIGAN AVENUE, SUITE 4000, CHICAGO, IL, 60611 · (312) 448-5500
Summary
Alerce Investment Management, L.P. reported $54M in U.S.-listed holdings across 7 positions for Q2 2022.
The portfolio is heavily concentrated: American Well alone accounts for 50.5% of reported value.
The book was largely unchanged from Q1 2022.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 59.2% · $32M
- Common Stock · 40.8% · $22M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ALRNEURAILERON THERAPEUTICS INC | HELD | +0 | 16.61M | −$4M | $4M |
| ANNXANNEXON INC | HELD | +0 | 1.95M | +$2M | $7M |
| WHWKAADI BIOSCIENCES INC | HELD | +0 | 374.8K | −$2M | $5M |
| AKBAAKEBIA THERAPEUTICS INC | HELD | +0 | 4.65M | −$2M | $2M |
| AMERICAN WELL CORP | HELD | +0 | 6.30M | +$693,000 | $27M |
| GBTUSDGLOBAL BLOOD THERAPEUTICS IN | HELD | +0 | 126.3K | −$340,000 | $4M |
| ASSEMBLY BIOSCIENCES INC | HELD | +0 | 2.23M | +$89,000 | $5M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | AMERICAN WELL CORP | CL A | 50.52% | $27M | 6.30M |
| 2 | ANNXANNEXON INChistory → | COM | 13.68% | $7M | 1.95M |
| 3 | ASSEMBLY BIOSCIENCES INC | COM | 8.68% | $5M | 2.23M |
| 4 | WHWKAADI BIOSCIENCES INChistory → | COM | 8.57% | $5M | 374.8K |
| 5 | ALRNEURAILERON THERAPEUTICS INChistory → | COM | 8.01% | $4M | 16.61M |
| 6 | GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory → | COM | 7.49% | $4M | 126.3K |
| 7 | AKBAAKEBIA THERAPEUTICS INChistory → | COM | 3.05% | $2M | 4.65M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2024 | $57M | 5 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $62M | 5 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $51M | 5 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $95M | 5 | May 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $75M | 5 | Feb 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $59M | 6 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $77M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $76M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $87M | 6 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $104M | 7 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $54M | 7 | Aug 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $59M | 7 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $98M | 7 | Feb 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $146M | 7 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $184M | 7 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $226M | 7 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $254M | 7 | Feb 11, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.